For nearly 30 years, Myoderm has been a specialist in global clinical trial supply, with deep expertise in sourcing, management, and labeling of commercial drugs and supplies. Our ingenuity, strategic thinking, and obsession with providing the most efficient, effective, and seamless supply solutions is why top pharmaceutical companies, biotech companies, CROs, and clinical trial packagers around the world rely on Myoderm for their supply needs. With headquarters in Europe and North America, and an extensive global network of manufacturers and suppliers, we pride ourselves on our proven ability to locate branded, generic and OTC products in all therapeutic classes and dosage forms – including the most hard-to-find medications. And, we are fully licensed for the storage and distribution of prescription medications including controlled drugs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

SUMITOVANT BIOPHARMA AND SUMITOMO PHARMA ANNOUNCE OFFER TO ACQUIRE OUTSTANDING SHARES OF MYOVANT SCIENCES

Sumitovant Biopharma Ltd. | October 03, 2022

news image

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash. The proposed transaction, if completed, would result in Myovant being delisted from the New York Stock Exchange. The proposed acquisition consideration repres...

Read More

XELLIA STARTS STERILE INJECTABLE PRODUCTION AT ONCE VILIFIED U.S. PLANT

FiercePharma | March 26, 2020

news image

After nearly five years and significant investment, commercial production is again underway at a plant that was once the poster-child of pharma production quality failures. Following a January inspection, the FDA has given its nod of approval for Xellia Pharmaceuticals to start manufacturing at the sterile injectables plant in the Cleveland, Ohio suburb of Bedford. The Copenhagen, Denmark-based Xellia says it will use the greater capacity to scale up its approved pipeline of antiinfectives and t...

Read More

Pharmacy Market

WUXI BIOLOGICS LAUNCHES FIRST COMMERCIAL DRUG PRODUCT FACILITY FOR PRE-FILLED SYRINGES

WuXi Biologics | June 06, 2022

news image

WuXi Biologics a global CRDMO service company, announced it has successfully launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi Biologics. The DP5 facility features an advanced isolator filling line for continuous and steady filling services, which offers multiple volume delivery options for pre-filled syringes including 1 mL Long, 1 mL, 2.25 mL and 3 mL. The m...

Read More

Pharma Tech

ASAHI KASEI PHARMA TO SPONSOR RESEARCH FOR DRUG DISCOVERY RESEARCH AND TECHNOLOGY: OPEN INNOVATION 2023

Asahi Kasei | October 17, 2022

news image

Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world. The application period begins at 5:00 a.m. GMT on January 5, 2023 and ends at 8:00 a.m. GMT on February 28, 2023. Asahi Kasei Pharm...

Read More
news image

Pharma Tech

SUMITOVANT BIOPHARMA AND SUMITOMO PHARMA ANNOUNCE OFFER TO ACQUIRE OUTSTANDING SHARES OF MYOVANT SCIENCES

Sumitovant Biopharma Ltd. | October 03, 2022

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash. The proposed transaction, if completed, would result in Myovant being delisted from the New York Stock Exchange. The proposed acquisition consideration repres...

Read More
news image

XELLIA STARTS STERILE INJECTABLE PRODUCTION AT ONCE VILIFIED U.S. PLANT

FiercePharma | March 26, 2020

After nearly five years and significant investment, commercial production is again underway at a plant that was once the poster-child of pharma production quality failures. Following a January inspection, the FDA has given its nod of approval for Xellia Pharmaceuticals to start manufacturing at the sterile injectables plant in the Cleveland, Ohio suburb of Bedford. The Copenhagen, Denmark-based Xellia says it will use the greater capacity to scale up its approved pipeline of antiinfectives and t...

Read More
news image

Pharmacy Market

WUXI BIOLOGICS LAUNCHES FIRST COMMERCIAL DRUG PRODUCT FACILITY FOR PRE-FILLED SYRINGES

WuXi Biologics | June 06, 2022

WuXi Biologics a global CRDMO service company, announced it has successfully launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi Biologics. The DP5 facility features an advanced isolator filling line for continuous and steady filling services, which offers multiple volume delivery options for pre-filled syringes including 1 mL Long, 1 mL, 2.25 mL and 3 mL. The m...

Read More
news image

Pharma Tech

ASAHI KASEI PHARMA TO SPONSOR RESEARCH FOR DRUG DISCOVERY RESEARCH AND TECHNOLOGY: OPEN INNOVATION 2023

Asahi Kasei | October 17, 2022

Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world. The application period begins at 5:00 a.m. GMT on January 5, 2023 and ends at 8:00 a.m. GMT on February 28, 2023. Asahi Kasei Pharm...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us